Oncology Corporate Profile
XBiotech is leading the commercialization of biological therapies, including the discovery and development of True Human™ antibodies. The Company's lead product candidate now in two unique Phase III registration studies represents a novel, breakthrough treatment for advanced colorectal cancer. XBiotech has also developed manufacturing technology to reduce infrastructure needs, lessen capital requirements and shorten lead times for development of biological drugs. New manufacturing technologies are at the heart of XBiotech's approach to next generation biological therapies, including the production of highly competitive biosimilar or biobetter products.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|Xilonix®||monoclonal (IgG1k) antibody||Cancer cachexia||III|
|Xilonix®||monoclonal (IgG1k) antibody||Colorectal cancer||III|
|Xilonix®||monoclonal (IgG1k) antibody||Non Small Cell Lung Cancer (NSCLC)||II|
|Onivyde® (+ MABp1)||irinotecan liposome injection||Pancreatic cancer||I|
View additional information on product candidates here »